Institut Català de la Salut
[Valenzuela PL] Physical Activity and Health Research Group (“PaHerg”), Research Institute of Hospital “12 de Octubre” (“imas12”), Madrid, Spain. Department of Systems Biology, University of Alcalá, Madrid, Spain. [Santalla A] Department of Sport and Computer Science, Section of Physical Education and Sports, Faculty of Sport, Universidad Pablo de Olavide, Sevilla, Spain. EVOPRED Research Group, Universidad Europea de Canarias, Tenerife, Spain. [Alejo LB] Physical Activity and Health Research Group (“PaHerg”), Research Institute of Hospital “12 de Octubre” (“imas12”), Madrid, Spain. Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain. [Merlo A] Gait & Motion Analysis Laboratory, Sol et Salus Hospital, Torre Pedrera di Rimini (RN), Italy. [Bustos A] Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain. [Castellote-Bellés L, Ferrer-Costa R] Servei de Bioquímica clínica, Laboratoris Clínics, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pinós T] Biomedical Research Networking Center on Rare Disorders (CIBERER), Barcelona, Spain. Grup de Recerca de Patologia Neuromuscular i Mitocondrial, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-05-16T08:21:22Z
2024-05-16T08:21:22Z
2024-05
Endurance; Glycogen storage disease; Supplement
Resistencia; Enfermedad por almacenamiento de glucógeno; Suplemento
Resistència; Malaltia per emmagatzematge de glucogen; Suplement
Background This study aimed to determine the effect of different carbohydrate (CHO) doses on exercise capacity in patients with McArdle disease—the paradigm of “exercise intolerance”, characterized by complete muscle glycogen unavailability—and to determine whether higher exogenous glucose levels affect metabolic responses at the McArdle muscle cell (in vitro) level. Methods Patients with McArdle disease (n = 8) and healthy controls (n = 9) underwent a 12-min submaximal cycling constant-load bout followed by a maximal ramp test 15 min after ingesting a non-caloric placebo. In a randomized, double-blinded, cross-over design, patients repeated the tests after consuming either 75 g or 150 g of CHO (glucose:fructose = 2:1). Cardiorespiratory, biochemical, perceptual, and electromyographic (EMG) variables were assessed. Additionally, glucose uptake and lactate appearance were studied in vitro in wild-type and McArdle mouse myotubes cultured with increasing glucose concentrations (0.35, 1.00, 4.50, and 10.00 g/L). Results Compared with controls, patients showed the “classical” second-wind phenomenon (after prior disproportionate tachycardia, myalgia, and excess electromyographic activity during submaximal exercise, all p < 0.05) and an impaired endurance exercise capacity (–51% ventilatory threshold and –55% peak power output, both p < 0.001). Regardless of the CHO dose (p < 0.05 for both doses compared with the placebo), CHO intake increased blood glucose and lactate levels, decreased fat oxidation rates, and attenuated the second wind in the patients. However, only the higher dose increased ventilatory threshold (+27%, p = 0.010) and peak power output (+18%, p = 0.007). In vitro analyses revealed no differences in lactate levels across glucose concentrations in wild-type myotubes, whereas a dose–response effect was observed in McArdle myotubes. Conclusion CHO intake exerts beneficial effects on exercise capacity in McArdle disease, a condition associated with total muscle glycogen unavailability. Some of these benefits are dose dependent.
Research by PLV is supported by a Sara Borrell postdoctoral contract granted by Instituto de Salud Carlos III (CD21/00138). PLV, DB-G and AL are funded by the Spanish Ministry of Economy and Competitiveness and Fondos Feder (Alejandro Lucia, Grant No. PI18/00139). TP is funded by the Spanish Ministry of Economy and Competitiveness and Fondos Feder (Tomàs Pinós, Grant No. PI22/00201). Funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.
Article
Published version
English
Exercici - Aspectes fisiològics; Glicogenosi; Hidrats de carboni; Medicaments - Eficàcia; PHENOMENA AND PROCESSES::Physiological Phenomena::Diet, Food, and Nutrition::Food::Dietary Carbohydrates; PHENOMENA AND PROCESSES::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Physical Endurance::Exercise Tolerance; DISEASES::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolism, Inborn Errors::Carbohydrate Metabolism, Inborn Errors::Glycogen Storage Disease::Glycogen Storage Disease Type V; PHENOMENA AND PROCESSES::Physiological Phenomena::Pharmacological and Toxicological Phenomena::Pharmacological Phenomena::Dose-Response Relationship, Drug; FENÓMENOS Y PROCESOS::fenómenos fisiológicos::dieta, alimentación y nutrición::alimentos::carbohidratos de la dieta; FENÓMENOS Y PROCESOS::fenómenos fisiológicos nerviosos y musculoesqueléticos::fenómenos fisiológicos musculoesqueléticos::resistencia física::tolerancia al ejercicio; ENFERMEDADES::enfermedades nutricionales y metabólicas::enfermedades metabólicas::alteraciones congénitas del metabolismo::trastornos congénitos del metabolismo de los carbohidratos::enfermedad por almacenamiento de glucógeno::enfermedad por almacenamiento de glucógeno tipo V; FENÓMENOS Y PROCESOS::fenómenos fisiológicos::fenómenos farmacológicos y toxicológicos::fenómenos farmacológicos::relación dosis-respuesta de medicamentos
Elsevier
Journal of Sport and Health Science;13(3)
https://doi.org/10.1016/j.jshs.2023.11.006
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F00201
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - VHIR [1655]